Cancer and industry groups file legal challenges to administration’s MFN rule

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Pharmaceutical and biotechnology industry groups, joined by cancer groups, filed legal challenges to an HHS rule that uses international reference prices to lower Medicare Part B prices.

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

Editor & Publisher

Login